These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28233446)

  • 21. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 22. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.
    Teló GH; Carvalhal GF; Cauduro CGS; Webber VS; Barrios CH; Fay AP
    Ann Oncol; 2017 Jan; 28(1):191-192. PubMed ID: 28043983
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of new-onset psoriasis while on anti-TNFalpha treatment.
    Matthews C; Rogers S; FitzGerald O
    Ann Rheum Dis; 2006 Nov; 65(11):1529-30. PubMed ID: 17038454
    [No Abstract]   [Full Text] [Related]  

  • 24. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab.
    Tammaro A; Persechino S; Abruzzese C; Narcisi A; Cortesi G; Parisella FR; Laganà B
    Int J Immunopathol Pharmacol; 2012; 25(2):499-501. PubMed ID: 22697082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.
    Mielke F; Schneider-Obermeyer J; Dörner T
    Ann Rheum Dis; 2008 Jul; 67(7):1056-7. PubMed ID: 18556453
    [No Abstract]   [Full Text] [Related]  

  • 26. [Infliximab-induced psoriasis in an adolescent with ulcerative colitis].
    García Morin M; González Ruiz De León E; Tolín Hernani M; Sánchez Sánchez C
    An Pediatr (Barc); 2014 Jan; 80(1):e18-9. PubMed ID: 22475462
    [No Abstract]   [Full Text] [Related]  

  • 27. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
    Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
    Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma.
    Kobari Y; Kondo T; Takagi T; Omae K; Nakazawa H; Tanabe K
    In Vivo; 2017; 31(4):769-771. PubMed ID: 28652455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriasiform drug eruption due to abatacept.
    Kato K; Satoh T; Nishizawa A; Yokozeki H
    Acta Derm Venereol; 2011 May; 91(3):362-3. PubMed ID: 21336469
    [No Abstract]   [Full Text] [Related]  

  • 31. [Infliximab-induced pustular psoriasis in a patient with Crohn's disease].
    Monteagudo Sánchez B; Cabanillas M; Ortiz-Marin S; Gallego-Ojea JC
    Gastroenterol Hepatol; 2009 Mar; 32(3):175-6. PubMed ID: 19233516
    [No Abstract]   [Full Text] [Related]  

  • 32. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
    Matsumura N; Ohtsuka M; Kikuchi N; Yamamoto T
    Acta Derm Venereol; 2016 Feb; 96(2):259-60. PubMed ID: 26270860
    [No Abstract]   [Full Text] [Related]  

  • 33. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
    Seki T; Yasuda A; Oki M; Kitajima N; Takagi A; Nakajima N; Miyajima A; Fukagawa M
    Tokai J Exp Clin Med; 2017 Sep; 42(3):115-120. PubMed ID: 28871578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
    J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
    [No Abstract]   [Full Text] [Related]  

  • 35. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasiform and pustular eruption induced by etanercept and infliximab.
    Kuhara T; Watanabe D; Iwahori Y; Tamada Y; Yamamura M; Matsumoto Y
    Eur J Dermatol; 2009; 19(4):388-9. PubMed ID: 19467963
    [No Abstract]   [Full Text] [Related]  

  • 37. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 38. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
    de Groot M; de Rie MA; Bos JD
    Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab.
    Adra N; Cheng L; Pili R
    Clin Genitourin Cancer; 2017 Jun; 15(3):e517-e519. PubMed ID: 28110836
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.